Processa Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $4.76M
- P/E (TTM)
- –
- Dividend yield
- –
About Processa Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing Next Generation Cancer therapies. The company identifies existing, widely used cancer treatments that exhibit high toxicity and treatment-limiting side effects, modifying their metabolism or distribution to improve safety and efficacy while lowering toxicity. Its oncology pipeline includes PCS6422 (NGC-Cap), an oral therapy combined with capecitabine currently evaluated for solid tumors such as advanced breast cancer, and PCS11T (NGC-Iri), an analog targeting solid tumors. In addition to its oncology pipeline, the company evaluates opportunities for non-oncology clinical assets, including PCS12852 for gastroparesis and PCS499 for primary glomerular diseases.
The company conducts clinical and preclinical development programs, including a Phase 2 trial for PCS6422 and preclinical evaluations for PCS11T. Processa Pharmaceuticals maintains corporate offices in Vero Beach, Florida, where its principal executive operations are located.
Summary of the business section of Processa Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Processa Pharmaceuticals, Inc.
- Founded
- 2011
- Headquarters
- Vero Beach, FL
- Address
- 601 21st Street, Suite 300 32960
- Phone
- (443) 776-3133
- Website
- processapharmaceuticals.com
- Employees
- 12, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Cherry Bekaert LLP, Tampa, Florida
Stock & identifiers
- Ticker
- PCSA
- Exchange
- Nasdaq
- IPO date
- Mar 7, 2014
- Shares outstanding
- 3M, Aug 7, 2026
- Public float
- $8.10M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-25 reverse, Mar 18, 2026; 1-for-25 reverse, Dec 17, 2025; 1-for-20 reverse, Mar 29, 2024; 1-for-20 reverse, Jan 22, 2024; 1-for-7 reverse, Mar 6, 2020; 1-for-7 reverse, Dec 23, 2019; 8-for-3, Apr 16, 2018; 1-for-7 reverse, Dec 8, 2017
- SEC CIK
- 1533743
- CUSIP
- 74275C403
- ISIN
- US74275C4033
- LEI
- 529900A51HZIE4XJB960
- EIN
- 45-1539785
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| George K. Ng | Chief Executive Officer, Director | 21,380 |
| David Young | Pres. Research & Development, Director | 24,412 |
| Russell Skibsted | Chief Financial Officer | 16,689 |
| Patrick Lin | Chief Business - Strategy Off | 14,853 |
| Wendy Guy | Chief Administrative Officer | 14,727 |
| Sian Bigora | Chief Development Officer | 7,748 |
| Sheila Gujrathi | Director | – |
| Geraldine Pannu | Director | 2,391 |
| James R. Neal | Director | 1,021 |
| Justin W. Yorke | Director | 2,099 |
| Khoso Baluch | Director | 2,528 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | – | $565.07K | $530.99K | $2 | – |
| FY2025 Peo | $673.30K | $565.07K | $530.99K | $2 | – |
| FY2024 | – | $288.39K | $286.24K | $13 | – |
| FY2024 George Ng | $521.03K | $288.39K | $286.24K | $13 | – |
| FY2024 Peo | $521.03K | $288.39K | $286.24K | $13 | – |
| FY2023 | – | $428.85K | $321.70K | $100 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 13, 2026, we had 12 full- and part-time employees.”
Corporate history
Events identified from SEC filings